Nature | News

How an Oregon cancer institute raised a billion dollars

Gains from two-year fund-raising frenzy will aid the early detection of tumours.

Article tools

OHSU

Nike co-founder Philip Knight lit a fundraising fire in 2013 when he pledged US$500 million to the Oregon Health & Science University if the institution could raise an equal amount.

Cancer researcher Brian Druker had no idea that a fund-raising gala would change his life. On 20 September 2013, armed with a speech that his wife had written for him, he waited patiently to be introduced by Philip Knight, the billionaire co-founder of sportswear brand Nike.

Knight was a friend and benefactor; a few years earlier, he and his wife Penny had donated US$100 million to the cancer centre that Druker directs at Oregon Health & Science University (OHSU) in Portland. But nothing had prepared Druker for what happened next. “Penny and I will donate $500 million to OHSU, if it is matched in pledges within two years in a fund-raising campaign,” Knight said, drawing gasps of surprise from the audience. “If the campaign raises $499 million, we are relieved of our pledge,” he added. Druker turned in shock to his wife. “What do I do now?,” he asked.

So began a frantic two-year scramble at the OHSU Knight Cancer Institute to boost its fund-raising — about $10 million in a good year — to $250 million annually. On 25 June, OHSU announced that it had reached its target in 22 months. It is the largest amount a US institution has ever raised to win a challenge grant, according to the Indiana University Lilly School of Philanthropy in Indianapolis.

“Publicly we were always very confident, because if you aren’t, people aren’t going to donate,” Druker says. “But when we first got started, we thought, ‘How are we going to do this?’”

“If there is a wealthy person in Oregon who hasn’t been asked to make a gift, I would be shocked.”

Billion-dollar campaigns are still relatively rare, says Bruce Flessner, a fund-raising consultant at Bentz Whaley Flessner in Minneapolis, Minnesota. And when universities do set out to raise that much, he notes, they typically take about seven years and dedicate the proceeds to all corners of the institution. The Knight Cancer Challenge aimed to fund a single institute at a university that is far from the clusters of wealth found in New York City or Silicon Valley.

“Portland is a great city, but it’s not minting billionaires at a fast rate,” says Flessner. “If there is a wealthy person in Oregon who hasn’t been asked to make a gift to that cancer programme, I would be shocked.”

But OHSU does have Druker, a renowned physician and researcher who made his name by laying the groundwork for the revolutionary leukaemia drug Gleevec (imatinib). The drug was approved by US regulators in 2001, and turned chronic myeloid leukaemia (CML) — once a death sentence for 70% of people diagnosed with it — into a long-term, manageable disease for 90% of patients.

Druker’s star power and Knight’s showmanship in designing and announcing the challenge galvanized the grass-roots fund-raisers. The campaign received more than 10,000 donations, given from 5 countries and every US state. Three-quarters of the money came from sources in Oregon. The largest single donation was $100 million from Gert Boyle, chair of the Oregon-based company Columbia Sportswear. Boyle’s late sister, a molecular biologist, died of brain cancer and was a scientific mentor to Druker when he was an undergraduate at the University of California, San Diego.

The campaign decided early on to approach Oregon’s state legislature for $200 million to construct two buildings for the cancer institute. OHSU pitched the expanded cancer centre to legislators as a way to create jobs for the state while fighting a disease that is the number-one killer of Oregonians. When the state senate approved the measure by a vote of 28–2 in March 2014, Druker began to believe that Knight’s challenge could be met.

But two months later, the campaign hit a public-relations snag when its advertising — designed to be catchy and blunt — suggested that Druker’s work on Gleevec had “cured” CML. The pitches angered some people with CML, who must take expensive drugs for the rest of their lives while enduring side effects and the fear that their cancer will become resistant to treatment. Patients said that calling Gleevec a cure would slow the search for better therapies. Druker issued an apology and OHSU toned down the adverts to read: “That’s one cancer down. Now we’re going after other cancers as aggressively as they come after us.”

With the money now in hand, it is time for Druker, OHSU and the cancer centre to deliver on that promise. Druker aims to rapidly hire up to 30 principal investigators, and to provide researchers with a funding cushion intended to free them from the burden of constantly applying for grants. But the investigators will also be expected to meet research milestones. “We want to make progress as quickly as we can,” he says.

The institute will focus on detecting cancers early in their development, when treatments generally have a better chance of success. Druker also wants the institute to take advantage of emerging technologies to develop better tests that would reduce false diagnoses.

He is eager to turn his full attention to the science, but already feels nostalgic about the past two years. “It’s been busy,” he says. “But it’s been quite a ride.”

Journal name:
Nature
Volume:
523,
Pages:
14–15
Date published:
()
DOI:
doi:10.1038/523014a

For the best commenting experience, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will see comments updating in real-time and have the ability to recommend comments to other users.

Comments for this thread are now closed.

Comments

Comments Subscribe to comments

There are currently no comments.

sign up to Nature briefing

What matters in science — and why — free in your inbox every weekday.

Sign up

Listen

new-pod-red

Nature Podcast

Our award-winning show features highlights from the week's edition of Nature, interviews with the people behind the science, and in-depth commentary and analysis from journalists around the world.